CurQD® Protocol BLUE+
CurQD® Protocol (BLUE+)
CurQD® Blue + offers intensive support for moderate health. Here’s everything you need for your recommended 6-week protocol.
4 capsules a day, that’s all it takes!
Not tested on animals
Lab Tested by third party
Crafted from naturally derived ingredients
-
Patent Pending
Couldn't load pickup availability
Developed by Leading IBD Researchers
CurQD® was developed in Sheba Medical Center (SMC), one of Newsweek’s best 10 hospitals in the world.
The protocol evolved from the clinical experience and placebo-controlled trials led by Nir Salomon, Director of the Integrative Gastroenterology unit at SMC, and Professor Shomron Ben-Horin MD, Chief of the Gastroenterology Department & Director of the Gastro-Immunology Research Laboratory Department of Gastroenterology SMC.
Warnings
Interactions:
Do not use if you have any liver disease, including but not limited to, autoimmune hepatitis or primary sclerosing cholangitis (PSC).
Allergen Warning:
May contain cereals with gluten, celery, soybeans, nuts, mustard, sesame seeds, molluscs.
Does not contain:
Eggs, fish, peanut, milk, lupin, crustations, sulfur dioxide & sulphites at a concentration of more than 10 mg/kg or 10 mg/1 expressed as S02.
Disclaimer:
Consult your physician before use if you are pregnant, nursing, have a medical condition or are taking any medications. Should only be used as directed. Keep out of reach of children. Store in a cool and dry place.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
FAQ
Are there any side effects?
* Headaches - commonly experienced in the first 72 hours of treatment.
*Mild transient elevation of liver enzymes - blood tests are recommended 3-6 weeks after starting CurQD (assessing ALT and AST).
* Shortness of breath.
* Chest pain.
*Palpitations (a sense of strong, irregular heartbeat).
* Jaundice.
* Any unexplained symptom.
* Qing Dai has on rare occasions been associated with pulmonary arterial hypertension (PAH) which dissipated upon discontinued use. Zero cases have been reported with CurQD.
Please note this is given only as general information and we always recommend consulting with your physician regarding any treatment decisions.